BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18576151)

  • 1. Methods for conversion of prion protein into amyloid fibrils.
    Breydo L; Makarava N; Baskakov IV
    Methods Mol Biol; 2008; 459():105-15. PubMed ID: 18576151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
    Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
    J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features.
    Baskakov IV; Bocharova OV
    Biochemistry; 2005 Feb; 44(7):2339-48. PubMed ID: 15709746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils.
    Bocharova OV; Breydo L; Salnikov VV; Baskakov IV
    Biochemistry; 2005 May; 44(18):6776-87. PubMed ID: 15865423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and fibrillation of full-length recombinant PrP.
    Makarava N; Baskakov IV
    Methods Mol Biol; 2012; 849():33-52. PubMed ID: 22528082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Core structure of amyloid fibrils formed by residues 106-126 of the human prion protein.
    Walsh P; Simonetti K; Sharpe S
    Structure; 2009 Mar; 17(3):417-26. PubMed ID: 19278656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions.
    Lührs T; Zahn R; Wüthrich K
    J Mol Biol; 2006 Mar; 357(3):833-41. PubMed ID: 16466741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates.
    Soto C; Estrada L; Castilla J
    Trends Biochem Sci; 2006 Mar; 31(3):150-5. PubMed ID: 16473510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methionine oxidation interferes with conversion of the prion protein into the fibrillar proteinase K-resistant conformation.
    Breydo L; Bocharova OV; Makarava N; Salnikov VV; Anderson M; Baskakov IV
    Biochemistry; 2005 Nov; 44(47):15534-43. PubMed ID: 16300402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro.
    Tagliavini F; Forloni G; Colombo L; Rossi G; Girola L; Canciani B; Angeretti N; Giampaolo L; Peressini E; Awan T; De Gioia L; Ragg E; Bugiani O; Salmona M
    J Mol Biol; 2000 Jul; 300(5):1309-22. PubMed ID: 10903871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of a spontaneously aggregating amyloid-forming variant of human PrP((90-231)) through phage-display screening of variants randomized between residues 101 and 112.
    Verma A; Sharma S; Ganguly NK; Majumdar S; Guptasarma P; Luthra-Guptasarma M
    Int J Biochem Cell Biol; 2008; 40(4):663-76. PubMed ID: 18023239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Full-length prion protein aggregates to amyloid fibrils and spherical particles by distinct pathways.
    El Moustaine D; Perrier V; Smeller L; Lange R; Torrent J
    FEBS J; 2008 May; 275(9):2021-31. PubMed ID: 18355314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein.
    Leliveld SR; Stitz L; Korth C
    Biochemistry; 2008 Jun; 47(23):6267-78. PubMed ID: 18473442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly of natural and recombinant prion protein into fibrils.
    Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
    Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semiautomated cell-free conversion of prion protein: applications for high-throughput screening of potential antiprion drugs.
    Breydo L; Bocharova OV; Baskakov IV
    Anal Biochem; 2005 Apr; 339(1):165-73. PubMed ID: 15766724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism at residue 129 modulates the conformational conversion of the D178N variant of human prion protein 90-231.
    Apetri AC; Vanik DL; Surewicz WK
    Biochemistry; 2005 Dec; 44(48):15880-8. PubMed ID: 16313190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prion Protein Prolines 102 and 105 and the Surrounding Lysine Cluster Impede Amyloid Formation.
    Kraus A; Anson KJ; Raymond LD; Martens C; Groveman BR; Dorward DW; Caughey B
    J Biol Chem; 2015 Aug; 290(35):21510-22. PubMed ID: 26175152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational plasticity of the Gerstmann-Sträussler-Scheinker disease peptide as indicated by its multiple aggregation pathways.
    Natalello A; Prokorov VV; Tagliavini F; Morbin M; Forloni G; Beeg M; Manzoni C; Colombo L; Gobbi M; Salmona M; Doglia SM
    J Mol Biol; 2008 Sep; 381(5):1349-61. PubMed ID: 18619462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does domain replacement affect fibril formation of the rabbit/human prion proteins.
    Yan X; Huang JJ; Zhou Z; Chen J; Liang Y
    PLoS One; 2014; 9(11):e113238. PubMed ID: 25401497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid formation of amyloid from alpha-monomeric recombinant human PrP in vitro.
    Tahiri-Alaoui A; James W
    Protein Sci; 2005 Apr; 14(4):942-7. PubMed ID: 15741327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.